The economic impact of premature mortality in Cabo Verde: 2016 - 2020

Abstract

Mortality analysis studies in Cabo Verde are rare and those that are available are limited to short periods of analysis and to specific population groups. Traditionally used mortality data does not quantify the burden resulting from premature mortality. This study focused on the years of potential life lost (YPLL), years of potential productive life lost (YPPLL) and the costs associated with them in Cabo Verde from 2016 to 2020 and aimed to elucidate the patterns of early mortality in the period analyzed. Mortality data were obtained from the Ministry of Health, Cabo Verde. Deaths that occurred from 2016 to 2020, aged between one (1) and 73 years old, were analyzed by sex, age group, municipality and cause of death. YPLL, YPPLL and cost of productivity lost (CPL) were estimated using life expectancy and the human capital approach. A total of 6100 deaths were recorded in the sample population and males represented 68.1% (n = 4,154) of the deaths. The total number of deaths verified corresponded to 145,544 YPLL, of which 69.0% (100,389) were attributed to males. There were 4,634 deaths of individuals of working age, and these resulted in 80 965 YPPLL, with males contributing 72.1% (58,403) of the total YPPLL. The total estimated CPL due to premature death was 98,659,153.23 USD with trauma accounting for the highest estimated losses of 21,580,954.42 USD (21.9%), followed by diseases of the circulatory system 18,843,260.42 USD (19.1%), and certain infectious and parasitic diseases accounted for 16,633,842.70 USD (16.9%). The study demonstrated the social and economic burden of premature mortality. The YPLL, YPPLL and CPL measures can be used to complement measures traditionally used to demonstrate the burden and loss of productivity due to premature mortality and to support resource allocation and public health policies making in Cabo Verde.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors received no specific funding for this work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

As this study analyzed existing secondary data provided by the National Directorate of Health and published in Annual Health Reports, submission to the National Ethics Committee for Health Research and to the National Commission for Data Protection was not required.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data underlying the results presented in the study are available from the National Directorate of Health, Ministry of Health, Cabo Verde

留言 (0)

沒有登入
gif